TENOFOVIR (TFV) ALAFENAMIDE (TAF) DOSE IN THE FIRST PIBASED SINGLE TABLET REGIMEN (STR) DARUNAVIR/COBICISTAT/EMTRICITABINE/TAF (DRV/COBI/FTC/TAF; D/C/F/TAF).

被引：0
|
作者：
Custodio, J. M. [1 ]
Wei, X. [1 ]
Wang, H. [1 ]
Hepner, M. [1 ]
Zack, J. Z. [1 ]
Callebaut, C. [1 ]
McCallister, S. [1 ]
Miller, M. [1 ]
Kearney, B. P. [1 ]
Ramanathan, S. [1 ]
机构：
[1] Gilead Sci Inc, Foster City, CA 94404 USA
来源：
CLINICAL PHARMACOLOGY & THERAPEUTICS | 2015年 / 97卷
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
PI-052
引用
收藏
页码：S36 / S36
页数：1
相关论文
共 50 条
  • [1] DRUG INTERACTION POTENTIAL OF EMTRICITABINE (F; FTC)/TENOFOVIR (TFV) ALAFENAMIDE (TAF) (F/TAF) FIXED DOSE COMBINATION AND COBICISTAT (COBI)-BOOSTED DARUNAVIR (DRV).
    Custodio, J. M.
    Wang, H.
    Silva, A.
    Zhong, L.
    Zack, J. Z.
    Callebaut, C.
    McCallister, S.
    Kearney, B. P.
    Ramanathan, S.
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2015, 97 : S72 - S72
  • [2] Real-world data on the use of the antiretroviral treatment (ART) regimen tenofovir alafenamide/emtricitabine/darunavir/cobicistat (TAF/FTC/DRV/c) and dolutegravir (DTG)
    Keane, A.
    Kelly, L.
    Keegan-Hickey, C.
    White, A.
    Heekin, A.
    Farrell, G.
    Moriarty, M.
    Devitt, E.
    Villa, G.
    [J]. HIV MEDICINE, 2023, 24 : 378 - 379
  • [3] Switching to a single-tablet regimen bictegravir, emtricitabine, and tenofovir alafenamide (B/F/TAF) from dolutegravir (DTG) plus emtricitabine and either tenofovir alafenamide or tenofovir disoproxil fumarate (F/TAF or F/TDF)
    Sax, P. E.
    Rockstroh, J.
    Luetkemeyer, A.
    Yasdanpanah, Y.
    Ward, D.
    Trottier, B.
    Rieger, A.
    Liu, H.
    Acosta, R.
    Collins, S. E.
    Brainard, D.
    Martin, H.
    [J]. JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2019, 22 : 3 - 4
  • [4] Steady-state pharmacokinetics of plasma tenofovir alafenamide (TAF), tenofovir (TFV) and emtricitabine (FTC), and intracellular TFV-diphosphate and FTC-triphosphate in HIV-1 infected old Japanese patients treated with bictegravir/FTC/TAF
    Tran, Hieu Trung
    Tsuchiya, Kiyoto
    Kawashima, Akira
    Watanabe, Koji
    Hayashi, Yoshiharu
    Ryu, Shoraku
    Hamada, Akinobu
    Gatanaga, Hiroyuki
    Oka, Shinichi
    [J]. GLOBAL HEALTH & MEDICINE, 2023, 5 (04): : 216 - 222
  • [5] TENOFOVIR ALAFENAMIDE (TAF) IN A SINGLE TABLET REGIMEN IN INITIAL HIV-1 THERAPY
    Pozniak, Anton
    Wohl, David
    Thompson, Melanie
    DeJesus, Edwin
    Podzamczer, Daniel
    Molina, Jean Michel
    Crofoot, Gordon
    Callebaut, Christian
    Martin, Hal
    McCallister, Scott
    [J]. SEXUALLY TRANSMITTED INFECTIONS, 2015, 91 : A49 - A49
  • [6] Efficacy and safety of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in combination with boosted darunavir (DRV) in treatment experienced patients with HIV
    Hill, L.
    Momper, J.
    Abulhosn, K.
    Ballard, C.
    Young, M.
    [J]. HIV MEDICINE, 2019, 20 : 81 - 81
  • [7] HIV-1/HCV Coinfection Treatment with Single-Tablet Antiviral Regimens (CoSTARs): 12 Weeks of Ledipasvir/Sofosbuvir (LDV/SOF) after Randomized Switch to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) or Rilpivirine/F/TAF (R/F/TAF)
    Ramgopal, Moti
    Jain, Mamta K.
    Hinestrosa, Federico
    Asmuth, David
    Huhn, Gregory
    Slim, Jihad
    Goldstein, Deborah
    Ryu, Julie
    Jiang, Shuping
    Das, Moupali
    Piontkowsky, David
    Rossaro, Lorenzo
    Haubrich, Richard
    Nguyen-Cleary, Thai
    [J]. HEPATOLOGY, 2017, 66 (06) : 1262A - 1263A
  • [8] The potential role of bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) single-tablet regimen in the expanding spectrum of fixed-dose combination therapy for HIV
    Stellbrink, H-J
    Lazzarin, A.
    Woolley, I
    Llibre, J. M.
    [J]. HIV MEDICINE, 2020, 21 : 3 - 16
  • [9] Effectiveness, persistence and safety of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF), rilpivirine/F/TAF (R/F/TAF) or F/TAF + another 3rd agent in HIV-1+patients over 24 months - Results from the German TAFNES cohort study
    Stellbrink, H.
    Scholten, S.
    Hillenbrand, H.
    Knechten, H.
    Jessen, H.
    Schreiber, S.
    Goerner, K.
    Haubrich, R.
    Heinzkill, M.
    [J]. JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2020, 23 : 54 - 55
  • [10] Efficacy and safety of the once-daily, darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) single-tablet regimen (STR) in ART-naive, HIV-1-infected adults: AMBER Week 96 results
    Orkin, C.
    Eron, J.
    Rockstroh, J.
    Podzamczer, D.
    Esser, S.
    Vandekerckhove, L.
    Van Landuyt, E.
    Lathouwers, E.
    Hufkens, V.
    Jezorwski, J.
    Opsomer, M.
    [J]. JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2018, 21
12345